Overcoming resistance to BRAF(V600E) inhibition in melanoma by deciphering and targeting personalized protein network alterations

BRAF(V600E) melanoma patients, despite initially responding to the clinically prescribed anti-BRAF(V600E) therapy, often relapse, and their tumors develop drug resistance. While it is widely accepted that these tumors are originally driven by the BRAF(V600E) mutation, they often eventually diverge a...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:NPJ Precis Oncol
Autors principals: Vasudevan, S., Flashner-Abramson, E., Alkhatib, Heba, Roy Chowdhury, Sangita, Adejumobi, I. A., Vilenski, D., Stefansky, S., Rubinstein, A. M., Kravchenko-Balasha, N.
Format: Artigo
Idioma:Inglês
Publicat: Nature Publishing Group UK 2021
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC8192524/
https://ncbi.nlm.nih.gov/pubmed/34112933
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41698-021-00190-3
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars